SC Declares End to Measles Outbreak Costing $2.1M

State Ends Six-Month Measles Outbreak with 997 Cases

South Carolina health officials have officially declared an end to a six-month measles outbreak that infected 997 people. The public health crisis, primarily affecting unvaccinated school-age children, incurred an estimated cost of $2.1 million to the state.

Outbreak Overview

The outbreak, which began in October 2025, was the largest single-location event in the United States since measles was declared eliminated in 2000. According to the South Carolina Department of Public Health, Spartanburg County was the epicenter, accounting for over 90% of infections. Data revealed that 932 of the 997 cases were in unvaccinated individuals, with children aged 5 to 17 being the most affected group with 639 cases.

Economic and Public Health Impact

The state's response to the outbreak cost an estimated $2.1 million. The crisis led to significant disruptions, with 874 students quarantined across 33 schools. However, the public health response also triggered a sharp rise in vaccinations. More than 81,000 measles vaccine doses were administered statewide, marking a 31% increase from 2025 figures.

Conclusion

While South Carolina has contained this local outbreak, the event occurs against a backdrop of rising national cases. The United States recorded 2,288 measles cases in 2025, the highest since 1991. The nation's measles elimination status is now under review by the Pan American Health Organisation, highlighting the broader economic and social risks associated with resurgent infectious diseases.

FAQ

Q: How much did the South Carolina measles outbreak cost?
A: The outbreak cost the state of South Carolina an estimated $2.1 million.

Q: How many people were affected by the measles outbreak?
A: A total of 997 people were infected, with data showing that 932 of them had not been vaccinated.

Q: Is measles still considered eliminated in the United States?
A: Measles was declared eliminated in the U.S. in 2000, but this status is currently under review by international health authorities due to a significant increase in national case numbers.

Source: investing.com